Scilex Holding Company (SCLX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 512.24M USD | Liabilities, Current |
| Cash and equivalents | 566.00K USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | 6.44M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 4.17M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $512.24M | $566.00K | (m) | $6.44M | $4.17M | (m) |
| 2026-03-31 | (m) | $501.75M | $3.35M | (m) | $10.65M | $4.53M | (m) |
| 2025-12-31 | (m) | $483.65M | $4.96M | (m) | $15.24M | $4.79M | (m) |
| 2025-09-30 | (m) | $358.95M | $878.00K | (m) | $11.94M | $1.08M | (m) |
| 2025-06-30 | (m) | $305.93M | $4.10M | (m) | $16.77M | $2.52M | (m) |
| 2025-03-31 | (m) | $275.74M | $5.80M | (m) | $10.62M | $3.02M | (m) |
| 2024-12-31 | (m) | $259.63M | $3.27M | (m) | $26.44M | $2.44M | (m) |
| 2024-09-30 | (m) | $281.54M | $77.00K | (m) | $31.58M | $2.40M | (m) |
| 2024-06-30 | (m) | $255.45M | $6.89M | (m) | $38.00M | $3.07M | (m) |
| 2024-03-31 | (m) | $252.73M | $1.82M | (m) | $29.72M | $3.49M | (m) |
| 2023-12-31 | (m) | $250.38M | $3.92M | (m) | $34.60M | $4.21M | (m) |
| 2023-09-30 | (m) | $228.58M | $1.95M | (m) | $16.43M | $3.94M | (m) |
| 2023-06-30 | (m) | $103.58M | $34.12M | (m) | $27.57M | $3.11M | (m) |
| 2023-03-31 | (m) | $64.60M | $5.07M | (m) | $19.24M | $2.27M | (m) |
| 2022-12-31 | (m) | $44.84M | $2.18M | (m) | $21.24M | $1.38M | (m) |
| 2022-09-30 | (m) | $809.29K | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $598.65K | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $41.00K | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $208.70K | $507.92K | $303.75K | (m) | (m) | (m) |
| 2021-09-30 | (m) | $43.57K | (m) | $139.41M | (m) | (m) | (m) |
| 2021-06-30 | (m) | $20.02K | (m) | $139.41M | (m) | (m) | (m) |
| 2021-03-31 | (m) | $17.21K | $314.92K | $139.40M | (m) | (m) | (m) |
| 2020-12-31 | (m) | $180.76K | $30.51K | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |